Khankari, NK and Murff, HJ and Zeng, C and Wen, W and Eeles, RA and Easton, RA and Easton, DF and Kote-Jarai, Z and Al Olama, AA and Benlloch, S and Muir, K and Giles, GG and Wiklund, F and Gronberg, H and Haiman, CA and Schleutker, J and Nordestgaard, BG and Travis, RC and Donovan, JL and Pashayan, N and Khaw, K-T and Stanford, JL and Blot, WJ and Thibodeau, SN and Maier, C and Kibel, AS and Cybulski, C and Cannon-Albright, L and Brenner, H and Park, J and Kaneva, R and Batra, J and Taixeira, MR and Pandha, H and Zheng, W and Fitzgerald, LM, PRACTICAL consortium, Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium, British Journal of Cancer, 115 pp. 624-631. ISSN 0007-0920 (2016) [Refereed Article]
Copyright 2016 Cancer Research UK.
Background: Prostate cancer is a common cancer worldwide with no established modifiable lifestyle factors to guide prevention. The associations between polyunsaturated fatty acids (PUFAs) and prostate cancer risk have been inconsistent. Using Mendelian randomisation, we evaluated associations between PUFAs and prostate cancer risk.
Methods: We used individual-level data from a consortium of 22 721 cases and 23 034 controls of European ancestry. Externally-weighted PUFA-specific polygenic risk scores (wPRSs), with explanatory variation ranging from 0.65 to 33.07%, were constructed and used to evaluate associations with prostate cancer risk per one standard deviation (s.d.) increase in genetically-predicted plasma PUFA levels using multivariable-adjusted unconditional logistic regression.
Results: No overall association was observed between the genetically-predicted PUFAs evaluated in this study and prostate cancer risk. However, risk reductions were observed for short-chain PUFAs, linoleic (ORLA = 0.95, 95% CI = 0.92, 0.98) and α-linolenic acids (ORALA = 0.96, 95% CI = 0.93, 0.98), among men < 62 years; whereas increased risk was found among men greater than or equal to 62 years for LA (ORLA = 1.04, 95% CI = 1.01, 1.07). For long-chain PUFAs (i.e., arachidonic, eicosapentaenoic, and docosapentaenoic acids), increased risks were observed among men < 62 years (ORAA = 1.05, 95% CI = 1.02, 1.08; OREPA = 1.04, 95% CI = 1.01, 1.06; ORDPA = 1.05, 95% CI = 1.02, 1.08).
Conclusion: Results from this study suggest that circulating ω-3 and ω-6 PUFAs may have a different role in the aetiology of early- and late-onset prostate cancer.
|Item Type:||Refereed Article|
|Keywords:||polyunsaturated fatty acids prostate cancer|
|Research Division:||Medical and Health Sciences|
|Research Group:||Oncology and Carcinogenesis|
|Research Field:||Cancer Genetics|
|Objective Group:||Clinical Health (Organs, Diseases and Abnormal Conditions)|
|Objective Field:||Cancer and Related Disorders|
|Author:||Fitzgerald, LM (Dr Liesel Fitzgerald)|
|Web of Science® Times Cited:||1|
|Deposited By:||Menzies Institute for Medical Research|
|Downloads:||7 View Download Statistics|
Repository Staff Only: item control page